Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat generalised pustular psoriasis (GPP) flares.

Psoriasis and Psoriatic Arthritis Alliance (PAPAA), 01923 672837 Psoriasis Association, 01604 251 620 You can also get support from your local Healthwatch. NICE is not responsible for the quality or ...

Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there is ...

A 54-year-old woman with well-controlled chronic plaque psoriasis presented with a 2-day history of painful rash and fever. Widespread erythematous patches with overlying, coalescing pustules were ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

Pepople in England and Wales with a rare and severe form of psoriasis are celebrating the news that they may soon be able to access a new, first-in-class treatment from Boehringer Ingelheim. NHS ...

Fast Five Quiz: Generalized Pustular Psoriasis How much do you know about generalized pustular psoriasis? Assess your knowledge with this quick quiz ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

A rare case of adalimumab-induced pustular psoriasis in a hidradenitis suppurativa patient was successfully treated with guselkumab, highlighting the value of IL-23 inhibitors in paradoxical reactions ...